Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biberach – page 27

668 clinical trials in Biberach, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biberach at a glance
668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

668 trials in Biberach

Open in trial search

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Adenocarcinoma pancreas

Not yet recruiting

Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:BioNTech SE

Study on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CCTX-001
  • Sponsor:CanCell Therapeutics

Nervous system disorder

Not yet recruiting

Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Biberach

What the registry says about research in the country

01 Eye Diseases and Related Research

In Biberach An Der Riss, much of the clinical trial activity is connected to eye diseases and broader investigational research in healthy volunteers. The studies are focused on understanding how new treatments are absorbed, how food affects them, and how they interact with other medicines.

  • Research involving Eye Diseases and unspecified disease areas
  • Studies in healthy volunteers and otherwise healthy participants
  • Trials exploring pharmacokinetics and medicine interactions
  • Work aimed at improving treatment use and safety for future care

These trials help clarify how candidate therapies behave in the body and support the development of better treatment options.

02 Pharmacokinetic Studies

A major part of the research landscape centers on pharmacokinetic trial work, especially in healthy people. These studies are designed to see how medicines are absorbed, distributed, and influenced by food or other drugs.

  • Testing how different formulations are taken up in the body
  • Checking the effect of food on medicine exposure
  • Evaluating possible drug-drug interactions
  • Supporting the safe development of new oral therapies

The goal is to build a clearer picture of how investigational medicines behave before wider clinical use.

03 Healthy Volunteer Trials

Many of the studies in this city involve healthy volunteer trial designs, which are used to test safety, tolerability, and how the body responds to new compounds. This research is essential for early evaluation of promising medicines.

  • Assessing how well new treatments are tolerated
  • Comparing tablet and injection-style formulations
  • Measuring exposure changes with common co-medications
  • Generating data that supports further clinical development

The emphasis is on careful observation of how healthy participants respond to study medicines.

04 Metabolic and Cardiovascular Research

Some trials also address broader metabolic and cardiovascular interests, including medicines studied for body weight-related conditions and heart effects. These projects aim to understand both benefit and safety across different formulations.

  • Research on therapies related to obesity and metabolism
  • Studies of heart-related effects and medicine exposure
  • Comparisons of separate versus combined medicine use
  • Support for better treatment planning in chronic disease care

This area reflects a wider effort to refine new treatments for complex health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.